WallStSmart
ZVRA

Zevra Therapeutics Inc.

NASDAQ: ZVRA · HEALTHCARE · BIOTECHNOLOGY

$10.17
+5.17% today

Updated 2026-04-30

Market cap
$585.24M
P/E ratio
7.33
P/S ratio
5.50x
EPS (TTM)
$1.35
Dividend yield
52W range
$7 – $13
Volume
1.1M

Zevra Therapeutics Inc. (ZVRA) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20122013201420152016201720182019202020212022202320242025
Revenue$12.84M$13.29M$28.65M$10.16M$27.46M$23.61M$106.47M
Revenue growth (YoY)+3.5%+115.6%-64.5%+170.3%-14.0%+350.9%
Cost of revenue$84000.00$175000.00$336000.00$324000.00$2.94M$1.30M$2.06M$222000.00$2.94M$7.42M$16.48M
Gross profit$-84000.00$-175000.00$-336000.00$-324000.00$9.89M$11.98M$26.59M$9.94M$24.52M$16.20M$89.99M
Gross margin77.1%90.2%92.8%97.8%89.3%68.6%84.5%
R&D$2.99M$3.37M$11.92M$13.93M$20.47M$20.59M$41.76M$19.41M$8.84M$10.16M$19.80M$39.81M$42.09M$12.74M
SG&A$2.34M$1.35M$4.53M$8.88M$14.00M$12.77M$12.51M$10.82M$7.92M$8.70M$15.34M$24.73M$54.87M$77.62M
Operating income$-5.34M$-4.72M$-16.44M$-22.81M$-37.48M$-33.37M$-55.90M$-20.34M$-5.61M$7.73M$-42.56M$-49.60M$-87.00M$-4.23M
Operating margin-158.4%-42.2%27.0%-418.9%-180.6%-368.5%-4.0%
EBITDA$368886.00$-4.65M$-16.37M$-22.73M$-34.30M$-33.03M$-53.94M$-17.73M$-5.43M$-7.89M$-25.53M$-43.54M$-76.40M$98.71M
EBITDA margin-138.1%-40.9%-27.5%-251.2%-158.6%-323.6%92.7%
EBIT$306322.00$-4.72M$-16.44M$-22.81M$-34.47M$-33.37M$-54.27M$-18.03M$-5.70M$-8.14M$-26.47M$-44.55M$-82.79M$94.66M
Interest expense$157000.00$2.72M$2.67M$7.13M$7.34M$7.09M$6.51M$7.09M$376000.00$335000.00$1.50M$7.35M$7.98M
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-70416.00$-5.23M$-24.45M$-54.66M$-16.52M$-43.39M$-56.47M$-24.52M$-12.76M$-8.55M$-26.77M$-46.05M$-105.51M$83.23M
Net income growth (YoY)-7321.6%-367.9%-123.5%+69.8%-162.7%-30.1%+56.6%+48.0%+33.0%-212.9%-72.0%-129.1%+178.9%
Profit margin-191.0%-96.0%-29.9%-263.5%-167.7%-446.9%78.2%